Cargando…

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer

BACKGROUND: High expression of immune checkpoints in tumor microenvironment plays significant roles in inhibiting anti-tumor immunity, which is associated with poor prognosis and cancer progression. Major epigenetic modifications in both DNA and histone could be involved in upregulation of immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasidharan Nair, Varun, El Salhat, Haytham, Taha, Rowaida Z., John, Anne, Ali, Bassam R., Elkord, Eyad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003083/ https://www.ncbi.nlm.nih.gov/pubmed/29983831 http://dx.doi.org/10.1186/s13148-018-0512-1

Ejemplares similares

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
por: Saleh, Reem, et al.
Publicado: (2020)

DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-β genes in HLA-DR(–) myeloid cells, compared with HLA-DR(+) antigen-presenting cells
por: Saleh, Reem, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
por: Malinga, Nonkululeko Z., et al.
Publicado: (2022)

Intratumoral FoxP3(+)Helios(+) Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer
por: Syed Khaja, Azharuddin Sajid, et al.
Publicado: (2017)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

CD4(+) T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
por: Fromentin, Rémi, et al.
Publicado: (2016)

The mechanisms of the pD --> $^{3}$H$_{\Lambda}$K$^{+}$ reaction
por: Komarov, V I, et al.
Publicado: (1995)

The Role of Hypoxia on the Trimethylation of H3K27 in Podocytes
por: Barth, Johanna, et al.
Publicado: (2023)

Decreased H3K27 and H3K4 trimethylation on mortal chromosomes in distributed stem cells
por: Huh, Y H, et al.
Publicado: (2014)

Comparative Analyses of H3K4 and H3K27 Trimethylations Between the Mouse Cerebrum and Testis
por: Cui, Peng, et al.
Publicado: (2012)

PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
por: Saleh, Reem, et al.
Publicado: (2019)

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021)

PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report
por: García-Muñoz, Alejandro, et al.
Publicado: (2020)

H3K36 trimethylation-mediated biological functions in cancer
por: Xiao, Chu, et al.
Publicado: (2021)

Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients
por: Kgokolo, Mahlatse C. M., et al.
Publicado: (2022)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

The Meiotic Recombination Activator PRDM9 Trimethylates Both H3K36 and H3K4 at Recombination Hotspots In Vivo
por: Powers, Natalie R., et al.
Publicado: (2016)

Histone H2BK123 monoubiquitination is the critical determinant for H3K4 and H3K79 trimethylation by COMPASS and Dot1
por: Nakanishi, Shima, et al.
Publicado: (2009)

Effects of Nickel Treatment on H3K4 Trimethylation and Gene Expression
por: Tchou-Wong, Kam-Meng, et al.
Publicado: (2011)

Dynamic Regulation of H3K27 Trimethylation during Arabidopsis Differentiation
por: Lafos, Marcel, et al.
Publicado: (2011)

Transcriptomic Profiling of Tumor-Infiltrating CD4(+)TIM-3(+) T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients
por: Sasidharan Nair, Varun, et al.
Publicado: (2020)

Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer
por: Benard, Anne, et al.
Publicado: (2014)

Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome
por: Ciraolo, Elisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lcob8i81lt7ju5ka3qe53s2ab5